Newly Approved Drugs
The FDA approved 11 new hematology-oncology drugs in 2012.
The Food and Drug Administration (FDA) had a busy year in 2012, with 11 new hematology-oncology drug approvals. Additional approvals for new indications added to the list. Of note is that the majority of new oncology drugs are oral agents. The complete list of all 2012 FDA drug approvals (cardiology, infectious disease, etc.) can be found at the FDA’s Center Watch website.
The 2012 hematology-oncology drug approvals or new indications include:
Abraxane (paclitaxel protein-bound particles for injectable suspension); Celgene; For the treatment of non-small cell lung cancer, Approved October 2012
Afinitor (everolimus); Novartis; for the treatment of hormone receptor-positive, HER2-negative breast cancer, Approved July 2012
Bosulif (bosutinib); Pfizer; for the treatment of Ph+ chronic myelogenous leukemia, Approved September 2012
Cometriq (cabozantinib); Exelixis; for the treatment of metastatic medullary thyroid cancer, Approved November 2012
Erivedge (vismodegib); Genentech; for the treatment of basal cell carcinoma, Approved January 2012
Iclusig (ponatinib); Ariad Pharmaceuticals; for the treatment of chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia, Approved December 2012
Inlyta (axitinib); Pfizer; for the treatment of advanced renal cell carcinoma, Approved January 2012
Kyprolis (carfilzomib); Onyx Pharmaceuticals; for the treatment of multiple myeloma, Approved July 2012
Marqibo (vinCRIStine sulfate LIPOSOME injection); Talon Therapeutics; for the treatment of Ph- acute lymphoblastic leukemia, Approved August 2012
Neutroval (tbo-filgrastim); Teva Pharmaceuticals; for the reduction in the duration of severe chemotherapy-induced neutropenia, Approved August 2012
Omontys (peginesatide); Affymax; for the treatment of anemia due to chronic kidney disease, Approved March 2012
Perjeta (pertuzumab); Genentech; for the first-line treatment of HER2+ metastatic breast cancer, Approved June 2012
Stivarga (regorafenib); Bayer HealthCare Pharmaceuticals; for the treatment of previously treated patients with metastatic colorectal cancer, Approved September 2012
Synribo (omacetaxine mepesuccinate); Teva Pharmaceuticals; for the treatment of chronic or accelerated phase chronic myeloid leukemia, Approved October 2012
Votrient (pazopanib); GlaxoSmithKline; for the treatment of soft tissue sarcoma, Approved April 2012
Xtandi (enzalutamide); Medivation; for the treatment of metastatic castration-resistant prostate cancer, Approved August 2012
Zaltrap (ziv-aflibercept); Sanofi Aventis US; for the treatment of metastatic colorectal cancer, Approved August 2012
FDA Approves Encorafenib Plus Cetuximab and Chemo in BRAF V600E-Positive Metastatic CRC
Published: December 20th 2024 | Updated: December 20th 2024The FDA has granted approval for the use of encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of metastatic colorectal cancer harboring a BRAF V600E mutation.
